ACW — Actinogen Medical Income Statement
0.000.00%
Last trade - 00:00- AU$87.72m
- AU$65.14m
- AU$0.29m
Annual income statement for Actinogen Medical, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.094 | 0.027 | 0.041 | 0.367 | 0.291 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.4 | 3.92 | 9.53 | 11 | 13.3 |
| Operating Profit | -5.3 | -3.89 | -9.49 | -10.6 | -13 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.33 | -3.92 | -9.5 | -10.8 | -13 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.33 | -3.92 | -9.5 | -10.8 | -13 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.33 | -3.92 | -9.5 | -10.8 | -13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.33 | -3.92 | -9.5 | -10.8 | -13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.004 | -0.003 | -0.005 | -0.006 | -0.006 |